<DOC>
	<DOCNO>NCT00054262</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness T900607 treat patient unresectable liver cancer .</brief_summary>
	<brief_title>T900607 Treating Patients With Unresectable Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete partial response rate patient chemotherapy-na√Øve unresectable hepatocellular carcinoma treat T900607 . - Determine efficacy drug , term duration response time disease progression , patient . - Determine pharmacokinetics drug patient . - Determine safety profile drug patient . OUTLINE : This multicenter study . Patients receive T900607 IV 1 hour weekly . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 20-35 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable hepatocellular carcinoma ( HCC ) Bidimensionally measurable disease define least 1 lesion 1 cm 2 dimension CT scan Class A B ChildPugh liver classification No prior CNS metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy At least 12 week Hematopoietic Absolute neutrophil count least 1,500/mm^3* Platelet count least 100,000/mm^3* Hemoglobin least 8.5 g/dL* NOTE : *More 7 day since prior blood transfusion growth factor Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) Albumin great 2.5 g/dL AST ALT great 3 time ULN INR great 1.5 ( unless receive anticoagulant ) Renal Creatinine great 2 time ULN Cardiovascular LVEF least 50 % No New York Heart Association class III IV cardiac disease No acute anginal symptom Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study No severe concurrent disease , infection , comorbidity would preclude study entry No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy HCC No concurrent therapeutic biological response modifier Chemotherapy No prior chemotherapy HCC No prior chemoembolization HCC No concurrent cytotoxic chemotherapy Endocrine therapy At least 6 week since prior hormonal therapy ( indicator lesion must exist outside area therapy No concurrent hormonal anticancer therapy Radiotherapy No prior radiotherapy HCC At least 6 week since prior radiofrequency ablation , selective internal radiation , embolization ( indicator lesion must exist outside area therapy ) No concurrent radiotherapy ( include palliative therapy ) Surgery At least 6 week since prior surgical resection ( indicator lesion must exist outside area therapy ) Recurrence margin surgical resection allow At least 6 week since prior cryosurgery More 4 week since prior major surgery Other More 4 week since prior investigational therapy At least 6 week since prior intratumoral ethanol injection ( indicator lesion must exist outside area therapy ) No concurrent investigational anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
</DOC>